Table S2.
Regimens
| Regimens | First-line chemotherapy | Second-line chemotherapy | Third-line chemotherapy |
|---|---|---|---|
| N | 118 | 65 | 31 |
| Platinum-based doublet | |||
| CDDP + CPT-11 | 14 | 24 | 1 |
| CDDP + VP-16 | 18 | 2 | 0 |
| CBDCA + VP-16 | 84 | 8 | 3 |
| CBDCA + CPT-11 | 1 | 0 | 1 |
| Nonplatinum doublet | |||
| AMR + CPT-11 | 1 | 0 | 0 |
| Nonplatinum monotherapy | |||
| AMR | 0 | 29 | 19 |
| CPT-11 | 0 | 2 | 4 |
| NGT | 0 | 0 | 3 |
| Concurrent thoracic radiotherapy | 25a | 0 | 0 |
Note:
a
Including one palliative thoracic radiotherapy.
Abbreviations: AMR, amrubicine; CBDCA, carboplatin; CDDP, cisplatin; CPT-11, irinotecan; NGT, topotecan; VP-16, etoposide.